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1. Introduction 
Yeast ribosomal resistance to trichodermin causes a
complex pleiotropic phenotype characterized by the 
different response of the peptidyl transferase c nter of 
the mutant 60S ribosomal subunits to its specific inhibi- 
tors as indicated by: (a) a higher level of resistance to 
other sesquiterpene antibiotics uch as fusarenon X 
and trichothecin [1,2] ; (b) a lower level of resistance 
to the chemically and biologicaly related sesquiterpene 
antibiotic verrucarin A [2] ; (c) cross-resistance to the 
antibiotic anisomycin [1,2] and the compound 
narciclasine [3] and (d) a supersensitivity to spars- 
omycin without alteration in the sensitivity to 
blasticidin S and gougerotin [4]. 
We have now extended those studies to the alkaloids 
haemanthamine, lycorine, pretazettine and pseudoly- 
corine which are chemically related to narciclasine 
(fig. 1) and also obtained from the bulbs of plants of 
the Amaryllidaceae family [5-8].  All these compounds 
OH OH  O H _oH 
,0 0 OH 
0 T I 
HO 0 
HAEMANTHAMINE LI CORINE NARCICLAS INE 
OH 
OH 
PRETAZETT INE PSEUDOLYCORINE 
inhibit the peptide bond formation step of protein 
synthesis catalyzed by eukaryotic ribosomes ([3,9] 
and results presented in this paper). Since those 
alkaloids are closely related in their chemical structure, 
biological activity and biological metabolism [5-8] 
they might be expected to share both a common mode 
of action and binding site. However the results present- 
ed in this paper show that a yeast mutant strain resist- 
ant to narciclasine and ribosomes from this mutant 
[3] display cross-resistance to pretazettine and 
haemanthamine but not to pseudolycorine and 
lycorine. These results trongly suggest hat haeman- 
thamine, narciclasine and pretazettine bind to the same 
area of the yeast ribosomal peptidyl transferase c nter 
while lycorine and pseudolycorine donot interfere 
with that site of this center. 
2. Material and methods 
The origin of our yeast (Saccharomyces revisiae) 
wild type strain sensitive to narciclasine (Y166) and 
the mutant (TR1) resistant to narciclasine isgiven 
elsewhere [2,3]. Liquid culture (YEP) and minimal 
media have been described [3,10]. Minimal inhibitory 
concentration was considered the amount of drug that 
under the standard conditions used (table 1) did not 
allow any visually appreciable growth of yeast after 
24 h of incubation. Preparation of yeast extracts, high 
salt washed ribosomes, polysomes and the partially 
purified supernatant fraction containing elongation 
factors EF 1 and EF 2 were carried out as described 
elsewhere [2]. Poly (U)- and endogenous mRNA- 
directed [14C]phenylalanine corporation i to 5% 
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TCA precipitable polypeptides was studied in ribosomal 
and polysomal systems, respectively [2]. Peptide bond 
formation was studied in the puromycin and the 
fragment reaction assays as reported [3,11 ]. 
Dr A. Battersby (University Chemical Laboratory, 
Cambridge, England) provided us with haemanthamine 
and lycorine; Dr C. Fuganti (Instituto di Chimica, 
Milano, Italy) with haemanthamine, lycorine, 
narciclasine and pseudolycorine; Dr E. Furusawa 
(School of Medicine, University of Hawaii, Honolulu) 
with lycorine, pretazettine and pseudolycorine; 
Dr H. Irie (Faculty of Pharmaceutical Sciences, Kyoto 
University, Japan) with haemanthamine and tazettine; 
Dr F. Piozzi (Instituto di Chimica Organica, Facolt~i di 
Scienze, Universit~ di Palermo, Italy) with narciclasine 
and Dr W. C. Wildman (Department of Chemistry, 
Iowa State University, USA) with haemanthamine and 
tazettine. 
3. Results 
3.1. The effects of  the alkaloids on yeast cell growth 
Table 1 shows the minimal inhibitory concentrations 
of several A maryllidaceae alkaloids for Y166 and TRI 
strains. Pretazettine does not inhibit cell growth of 
either Y166 or TR~ strains in YEP medium, pH 7.5 
[10] at concentrations up to 2 × 10 -3 M. This lack of 
activity could be due either to a permeability barrier 
of the cells to the charged form of pretazettine at the 
pH 7.5 of  the medium or to a conversion of the 
alkaloid to the inactive compound tazettine which 
takes place at alkaline pH [7]. However pretazettine 
did inhibit Y166 cell growth in the minimal medium 
(table 1). From the results presented in table 1 it is 
clear that TR1 cells are as sensitive to lycorine and 
pseudolycorine asY166 cells. On the other hand there 
is cross-resistance to narciclasine and pretazettine in
TRI strain (table 1). Haemanthamine, another alkaloid 
used in this study, was not active in either YEP or 
minimal media at concentrations up to 4 X 10 -3 M 
(table 1). 
3.2. The effects of the alkaloids on in vitro polypeptide 
synthesis by extracts from yeast strains 
Genetic studies have shown that there is a single 
mutation in the TR1 strain is nuclear [2 -4 ] .  Therefore 
it might be expected that the cross-resistance observed 
Table 1 
Minimal inhibitory concentrations ofthe alkaloids for 
Y166 and TR 1 ceils 
Drug Minimum inhibitory 
concentration (M) 
Y166 TR~ 
Haemanthamine a >4 × 10 -a >4 × 10 -3 
Haemanthamine b >4 × 10 -a >4 × 10 -3 
Lycorine a 2 X 10 -4 2 × 10 -4 
Narciclasine a 2 × 10 -4 > 10 -a 
Pretazettine a >2 × 10 -a >2 × t0 -a 
Pretazettine b 2 × 10 -a > 10 -2 
Pseudolycorine a 4 × 10 -3 4 × 10 -a 
Yeast growing logarithmically was diluted with either YEP, 
pH 7.5 (a) or minimal (b) media t 106 cells/ml. 1 ml aliquots 
of these suspensions were added to sterile tubes containing 
several dilutions of the required rug. Incubations were at 
37°C in YEP medium and at 30°C in minimal medium. After 
24 h incubation cell growth was determined by simple obser- 
vation of the cultures. 
in vivo to several A maryllidaceae alkaloids was due to 
the alteration induced by the TR~ mutation in the 
ribosome. The results presented in table 2 show that 
the alkaloids inhibit protein synthesis upported by 
either ribosomes or polysomes from the wild type 
yeast. The exception is lycorine which, at the con- 
centrations used, does not affect polyphenylalanine 
synthesis. This situation is not unique, since an ample 
number of inhibitors of protein synthesis like chloram- 
phenicol [ 12], erythromycin [ 12] and trichodermin 
[13] are very poor inhibitors of poly (U)-directed cell- 
free systems for polyphenylalanine synthesis. Although 
haemanthamine does not inhibit growth of intact yeast 
it is an active inhibitor of  protein synthesis in cell-free 
systems from the wild strain. Table 2 also shows that 
cell-free polypeptide synthesis by extracts from mutant 
cells is much less sensitive to haemanthamine and preta- 
zettine than synthesis by extracts from wild type 
strain. A similar result was previously found for 
narciclasine ([3] and table 2). However ibosomes and 
polysomes from Y166 and TR~ strains have a similar 
sensitivity to lycorine and pseudolycorine. 
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Table 2 
The effect of alkaloids on yeast ribosomes endogenous RNA-directed polypeptide 
and poly(U)-directed polyphenylalanine synthesis 
Drug Concentration % Control 
Polyphenylalanine Endogenous 
synthesis incorporation 
Y166 TR t Y166 TR I 
Haemanthamine 10 -4 M 64 97 20 90 
10 -3 M 34 100 11 72 
Lycorine 7 x 10 -s M 100 100 72 60 
7 × 10 -4 M 100 100 61 50 
Narciclasine 10 -5 M 13 57 8 35 
Pretazettine 5 X 10 -5 M 44 99 13 89 
2 × 10 -4 M 7 92 4 63 
Pseudolycorine 10-* M 42 45 60 52 
10 -3 M 38 32 46 40 
The reactions took place for 25 min or 15 min for poly(U)- or endogenous mRNA-directed 
polypeptide synthesis respectively. Other conditions as described in Materials and methods. 
Incorporation i the controls in the absence of drug was 175.13 or 16.38 (Y166 extracts) and 
220.9 or 17~97 (TR~ extracts) pmol of [14C]phenylalanine for poly(U)- or endogenous mRNA- 
directed polypeptide synthesis respectively. 
Table 3 
Effect of alkaloids on peptide bond formation by yeast polysomes and ribosomes 
Drug Concentration % Control 
(M) 
Peptidyl-PM 'Fragment reaction' 
formation 
Haemanthalnine 
Lycorine 
Narciclasine a 
7× 
7X 
Pretazettine 4 X 
4× 
Pseudolycorine 
Y166 TR~ Y166 TR~ 
10 -4 39 90 64 97 
10 -3 13 63 34 100 
10 -s 62 54 36 12 
10-" 28 20 6 0 
10 -7 - - 51 97 
10 -~ 58 99 5 48 
10 -s 5 30 - - 
10 -s 27 99 44 99 
10 -4 13 77 7 92 
10 -4 66 50 34 10 
10 -3 32 19 5 0 
The reactions were carried out as described in Materials and methods. Reactions in the controls 
in the absence of inhibitors amounted to 3.86 an d 0.19 pmol of peptidyl- [ 3 H ] puromycin and 
Ac-[3H]leucyl-puromycin respectively, aData taken from [3]. 
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3.3. The effects of the alkaloids on the peptide bond 
formation step of protein synthesis 
The alkaloids under study are closely related in their 
biological origin, chemical structure and mode of action, 
Also narciclasine has been shown to inhibit specifically 
the formation of the peptide bond [9]. Therefore we 
have studied the effects of the alkaloids on the activity 
of the peptidyl transferase c nter of the yeast cyto- 
plasmic ribosomes, in order to characterize their mode 
of action more precisely. Indeed table 3 shows that the 
five alkaloids inhibit the formation of Ac-[aH] Leu- 
puromycin (fragment reaction assay) and peptidyl- 
[3H]puromycin (puromycin reaction) in cell-free 
systems from the sensitive strain. Therefore the com- 
pounds halt the peptidyl transferase activity of the 
yeast ribosome, as previously shown with narciclasine 
[9]. In addition table 3 shows that the resistance 
towards haemanthamine and pretazettine atthe peptide 
bond formation step was similar to that previously 
observed with narciclasine. However ibosomes from 
the mutant are sensitive to lycorine and pseudolycorine. 
Furthermore it is interesting that in the well resolved 
'fragment reaction' assay, ribosomes of the mutant 
strain are even more sensitive to lycorine and pseudo- 
lycorine than the ribosomes from the wild type strain. 
towards parsomycin [2-4].  Furthermore mutant 
ribosomes are cross resistant in vitro to pretazettine 
and haemanthamine but sensitive to lycorine and 
pseudolycorine (tables 2 and 3). 
Haemanthamine, pretazettine and narciclasine 
appear to have a common binding site on the peptidyl 
transferase c ntre of the 60S ribosomal subunit. On 
the other hand lycorine and pseudolycorine apparently 
bind to a different site on the peptidyl transferase 
centre. The binding site of lycorine and pseudolycofine 
might be different from that of narciclasine; an 
alternative explanation could be that lycorine, 
pseudolycorine and narciclasine bind to the same or 
overlapping sites but the conformational modification 
induced by the TR1 mutation in the ribosome might 
impair the binding of narciclasine without affecting the 
interaction of lycorine and pseudolycorine. Further- 
more the binding sites of lycorine and pseudolycorine 
might be somehow related to the interaction site of 
sparsomycin since the three compounds show a higher 
inhibitory effect on peptide bond formation by ribo- 
somes of the TRI mutant [4] (table 3). Binding 
experiments with the radioactive alkaloids might help 
to elucidate this problem. 
4. Discussion 
The A maryllidaceae alkaloids tudied here have a 
potent antitumor activity [ 14,15]. The results present- 
ed in this paper show that haemanthamine, lycorine, 
pretazettine and pseudolycorine inhibit protein 
synthesis in yeast cell-free systems by blocking the 
peptide bond formation step, as previously reported 
with the chemically and biologically related substance 
narciclasine [9]. Pretazettine (initially known as 
residual alkaloid A-3) inhibits the reverse transcriptase 
in cell-free systems at rather high concentrations 
(4 mg/ml) [16]. Furthermore this alkaloid and 
pseudolycorine have been reported as preferentially 
inhibiting protein synthesis in tumor cells [ 17]. 
The yeast mutant strain TR1 has a single mutation 
with pleiotropic effects on the peptidyl transferase 
centre of the ribosome. Thus ribosomes from the TR1 
strain are resistant both in vivo and in vitro to some 
sesquiterpene antibiotics [2], anisomycin and 
narciclasine with enhancement i  their sensitivity 
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